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Abstract
The kinase MEKK2 (MAP3K2) may play an important role in tumor growth and metastasis for 
several cancer types. Thus, targeting MEKK2 may represent a novel strategy for developing more 
effective therapies for cancer. In order to identify small molecules with MEKK2 inhibitory 
activity, we screened a collection of known kinase inhibitors using a high throughput MEKK2 
intrinsic ATPase enzyme assay and confirmed activity of the most potent hits with this primary 
assay. We also confirmed activities of these known kinase inhibitors with an MEKK2 
transphosphorylation slot blot assay using MKK6 as a substrate. We observed a good correlation 
in potencies between the two orthogonal MEKK2 kinase activity assay formats for this set of 
inhibitors. We report that ponatinib, AT9283, AZD7762, JNJ-7706621, PP121 and hesperadin had 
potent MEKK2 enzyme inhibitory activities ranging from 4.7 – 60 nM IC50. Ponatinib is an FDA-
approved drug that potently inhibited MEKK2 enzyme activity with IC50 values of 10 – 16 nM. 
AT9283 is currently in clinical trials and produced MEKK2 IC50 values of 4.7 – 18 nM. This set 
of known kinase inhibitors represents some of the most potent in vitro MEKK2 inhibitors reported 
to date and may be useful as research tools. Although these compounds are not selective for 
MEKK2, the structures of these compounds give insight into pharmacophores that potently inhibit 
MEKK2 and could be used as initial leads to design highly selective inhibitors of MEKK2.
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The ERK5 signaling pathway is one of the mitogen-activated protein kinases (MAPK) 
signaling pathways that translate extra-cellular stimuli into gene expression changes in the 
cell [1,2]. This pathway is activated in response to oxidative stress, hyperosmolarity, and 
growth factors, including epidermal growth factor (EGF) [3]. ERK5 is activated through 
phosphorylation by the MAPK kinase Mek5 (MAP2K5). Mek5 in turn is activated through 
phosphorylation by the MAPK kinase kinases MEKK2 (MAP3K2) and MEKK3 
(MAP3K3). How MEKK2 is activated by external stimuli is still not fully understood, but 
MEKK2 autophosphorylates in response to stimuli and this autophosphorylation is required 
for activation of MEKK2 [4]. MEKK2 also activates the JNK MAPK pathway via 
phosphorylation of the MAP2K MEK7 which activates JNK [5,6]. MEKK2 knock-out mice 
displayed normal development and fertility [5,7]. In contrast, disruption of the MEKK3 gene 
in mice results in embryonic lethality due to cardiac development defects [8]. Thus, MEKK2 
and MEKK3 integrate different stimuli. MEKK2 has been reported to be activated by cell 
attachment to fibronectin and to subsequently localize to focal adhesions. MEKK2 
knockdown in breast cancer cell lines was shown to stabilize focal adhesions and inhibit cell 
migration in vitro [9,10].
The role of the MEKK2 in cancer has only relatively recently been explored. In one study 
linking MEKK2 to cancer, MEKK2 was expressed at 4.4-fold higher level in prostate cancer 
tissue versus benign tissue [11]. Even higher levels of MEKK2 were observed in prostate 
cancer cell lines. The microRNA miR-520b suppresses tumor formation in breast cancer and 
hepatocellular carcinoma cells by targeting MEKK2 and Cyclin D1 [12]. Knock-down of 
only MEKK2 expression was able to inhibit the growth of hepatocarcinoma cells in vitro 
and in vivo. The methylation of MEKK2 by SMYD3 was shown to increase MAP kinase 
signaling and promote the formation of Ras-dependent carcinomas [13]. Restoration of the 
expression of the tumor suppressor miR17/20a was shown to enhance tumor cell sensitivity 
to natural killer cell activity through suppressing MEKK2 [14]. A survey of primary 
colorectal cancer (CRC) lesions for MEKK2 expression level by western blotting indicated 
that MEKK2 was highly expressed in CRC compared to normal mucosa [15]. We used a 
mouse xenograft model of breast cancer to assess the role of MEKK2 in tumor growth and 
metastasis [16]. Using the breast cancer cell line MDA-MB-231, we observed that shRNA-
mediated knockdown of MEKK2 inhibited activation of ERK5 in response to EGF. 
Knockdown of MEKK2 expression had no observable impact on the growth of the cells in 
culture, but strongly inhibited both tumor growth and metastasis in the animal model. The 
tumors formed by the MEKK2 knock-down cells had increased apoptosis compared to size-
matched control tumors. MEKK2 shRNA knockdown in the BT474 breast cancer cell line 
also resulted in reduced tumor growth in vivo. Since ERK5 is activated by MEKK2 (via 
activation of MEK5), we determined whether shRNA knockdown of ERK5 in MDA-
MB-231 cells would show similar inhibition of tumor growth and metastasis as the MEKK2 
knockdown. The knockdown of ERK5 in these cells inhibited their ability to metastasize 
without significantly impacting tumor growth. Thus, MEKK2-mediated activation of ERK5 
appeared to regulate metastasis, while another MEKK2-dependent pathway, possibly the 
JNK pathway, was important for tumor growth.
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Overexpression or over-activation of ERK5 protein in humans coupled with in vitro and 
animal model data has begun to implicate a role for ERK5 in breast and prostate cancer as 
well as neuroblastoma, myeloma and oral squamous cell carcinoma [17,18,19,20,21]. The 
discovery of a potent and selective small molecule ERK5 inhibitor has been reported that 
inhibited tumor growth in mouse models of cancer [22]. MEK5 may also play a role in 
tumor development. Elevated tissue expression of MEK5 correlated with bone metastasis 
and poor prognosis in cases of prostate cancer and benign prostatic hypertrophy [23]. Two 
relatively selective MEK5 inhibitors have been reported, but no in vivo efficacy data were 
shown [24].
Taken together, literature data supports MEKK2 as a novel drug target for certain cancers. 
Targeting MEKK2 may be advantageous over inhibiting single MAPK pathways since an 
MEKK2 inhibitor may blunt activation of both the Erk5 and JNK pathways leading to 
enhanced anti-tumor efficacy. However, no specific and potent small molecule inhibitors of 
MEKK2 have been reported to date. Even without regard to selectivity, few potent inhibitors 
have been reported for MEKK2. Herein, we report the identification of 6 well-characterized 
kinase inhibitors that have previously un-reported potent MEKK2 inhibitory activity.
Materials and Methods
Materials
Common reagents such as HEPES, MgCl2 and dimethyl sulfoxide (DMSO) were reagent 
grade quality and obtained from Sigma-Aldrich (St. Louis, MO) or Thermo Fisher Scientific 
(Waltham, MA). The kinase inhibitor library (cat #L1200) and individual kinase inhibitors 
for confirmation were obtained from Selleck Chemicals (Houston, TX).
MEKK2 Enzyme Activity Assays
The MEKK2 intrinsic ATPase activity assay and the transphosphorylation assay were 
performed as previously described [25]. MEKK2 activity assays were performed using ATP 
concentrations at the apparent Km for ATP of the assay format. The Km for ATP was 
previously reported for the ATPase assay to be 34 uM and therefore the assay employed 30 
uM ATP. The Km for ATP in the transphosphorylation assay was previously reported to be 
3.3 uM and therefore we used 3 uM ATP for this assay.
IC50 value determinations
IC50 was defined as the concentration of inhibitor that generates a 50% reduction in the 
specific signal of the assay. Compounds were dissolved at 10 mM in 100% DMSO to make 
stock solutions. Serial dilutions of compounds were performed in 100% DMSO then 
subsequently diluted into assay buffer and used in the MEKK2 enzymatic assay. The slot 
blot transphosphorylation digital bands were quantified using software on the Kodak 4000R 
Pro imaging station. For both MEKK2 assay formats, compound concentration response 
curves were generated using data points that represent the average of 2 or 3 determinations 
per concentration and 10 compound concentrations tested. All IC50 values provided are 
averages of at least three (ATPase assay) or two (transphosphorylation assay) independent 
determinations. The IC50 values were calculated from concentration response data using 
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GraphPad Prism software (GraphPad Software Inc., La Jolla, CA) employing either a four- 
or three-parameter curve fit.
Results and Discussion
We have previously reported the development and validation of a novel intrinsic ATPase 
activity assay for MEKK2 and demonstrated its utility as a high throughput assay for the 
discovery of small molecule inhibitors of MEKK2 [25]. This assay takes advantage of 
intrinsic ATPase activity of MEKK2 wherein MEKK2 alone, in the absence of any protein 
substrates, converts ATP to ADP. After stopping the reaction, relative ADP levels were then 
measured, with the ADP-Glo kit (Promega, Inc.). We have used this assay to screen a 
commercial library of 195 known and well-characterized kinase inhibitors. We chose the 7 
most potent hits for further confirmation. Bosutinib was one these top hits, but we have 
previously reported it to have potent activity against MEKK2, with an IC50 of 59 nM [25]. 
We report the identification of 6 other known kinase inhibitors with previously unknown 
potent MEKK2 inhibitory activity. These kinase inhibitors and their IC50 values (nM, ±SD) 
in the MEKK2 ATPase assay were ponatinib (16 ± 3), AT9283 (18 ± 10), AZD7762 (20 ± 
7), JNJ-7706621 (24 ± 8), PP121 (30 ± 16) and hesperidin (60 ± 25) (Fig. 1 and Table 1). 
Average Hill slope values of the dose response curves for each compound were close to the 
expected value of 1.0, ranging from 0.85 to 1.18.
Since the ATPase kinase activity format is still novel, a completely different 
transphosphorylation MEKK2 assay format was used to confirm the activity observed in the 
ATPase assay. In this MEKK2 activity assay, native transphosphorylation activity of 
MEKK2 was measured using mutant kinase-inactive MKK6 (MAP2K6) as a substrate [25]. 
Enzyme reactions were performed in a 96-well plate format, stopped and applied in diluted 
form (to dilute out detergent which prevents membrane binding) to membrane by using a 
slot blot apparatus. The site-specific phosphorylation of MKK6 was detected by an anti-
phosphoMKK6 antibody and western blot processing. An image of a typical slot blot 
obtained with this method is provided as an example of the data obtained with this unique 
transphosphorylation assay (Fig. 2A). The intensity of the bands was quantified from 
software built into the image reader and used to create dose response graphs and obtain IC50 
values. The IC50 values (nM, ±SD) obtained in the MEKK2 transphosphorylation assay 
were as follows: ponatinib (10 ± 4), AT9283 (4.7 ± 0.9), AZD7762 (14 ± 2), JNJ-7706621 
(17 ± 2), PP121 (7 ± 0.3) and hesperadin (34 ± 11) (Fig. 2B and Table 1). Average Hill 
slope values of the dose response curves for each compound in this assay were close to the 
expected value of 1.0, ranging from 0.85 to 1.46. In comparing the data from the two 
different assay formats, there was less than a 2-fold difference between potencies obtained 
with the ATPase assay and those obtained with the transphosphorylation assay for 4 of the 
compounds and approximately a 4-fold difference for two of the compounds. Thus, all of 
these inhibitors confirmed activity in both MEKK2 assay formats. This comparison also 
strengthens the validation of the MEKK2 intrinsic ATPase assay as a homogeneous method 
of testing compounds for MEKK2 inhibitory activity.
Ponatinib (AP24534, Iclusig) is a Food and Drug Administration (FDA)-approved drug with 
an approved indication for chronic myeloid leukemia [26]. Ponatinib was originally 
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designed as an inhibitor of Abl (IC50 = 8.6 nM) and clinically relevant mutants of Abl, 
including Abl (T315I) (IC50 = 40 nM), in order to prevent drug resistance from developing 
[27]. It is also a multi-targeted tyrosine kinase inhibitor with low nM potency against FLT3, 
FGFR and VEGFR. In fact, it has been reported to be a potent pan-FGFR inhibitor with 
activity in animal models of FGFR-dependent cancers [28]. Remarkably, the IC50 values for 
inhibiting MEKK2 reported here for ponatinib are similar to the potency of ponatinib against 
its original target, Abl. This suggests the possibility that ponatinib could inhibit MEKK2 in 
patients and thus may be repurposed for cancers that are dependent on MEKK2 signaling. 
However, the potency of ponatinib to inhibit MEKK2 activity in cells would first need to be 
established.
AT9283 is a multi-targeted kinase inhibitor that has been reported to potently inhibit Aurora 
A and B (IC50 = 3 nM), JAK2/3 (IC50 = 1 nM), Abl (T315I) mutant (IC50 = 4 nM) and 10 
other kinases (1–10 nM) [29]. This compound has been tested in multiple phase I clinical 
trials in humans with advanced solid tumors and non-Hodgkin’s lymphoma and it appears to 
be well tolerated [30,31,32]. Phase II clinical trials with AT9283 are ongoing. This is the 
first report of AT9283 having potent MEKK2 inhibitory activity. The potency in our in vitro 
assays against MEKK2 (4.7 and 18 nM) suggests the possibility that AT9283 may inhibit 
MEKK2 in cell-based assays and in vivo.
AZD7762 was developed to target Chk1/2 (IC50s = 5 nM), but also potently inhibits other 
kinases including 9 members of the CAM kinase family and 20 tyrosine kinases [33]. 
AZD7762 entered Phase I clinical trials, but its development was terminated due to 
unpredictable cardiac toxicity [34]. JNJ-7706621 is a research tool compound that was 
reported to be a pan-CDK inhibitor, but it most potently inhibited CDK1, CDK2, CDK3, 
AuroraA and AuroraB with IC50s ≤15 nM [35]. Reported profiling data on JNJ-7706621 in 
single point determinations indicate that this compound also inhibits many other kinases 
[36]. A systematic effort to discover inhibitors that potently inhibit both TKs and PI3Ks led 
to the discovery of the novel multitargeted tool inhibitor PP121 [37]. This broadly active 
compound blocked the proliferation of tumor cells [38]. Hesperadin was discovered to be a 
potent inhibitor of chromosome alignment and segregation [39]. This research tool 
compound was also shown to be an inhibitor of Aurora B (IC50 = 250 nM) and other kinases 
[40]. The structures of this set of kinase inhibitors are fairly diverse, except that 4 of them 
have in common an indole-like motif (Table 1). Also, five of these compounds have a 5-
member heterocycle as part of the core of the structure.
In sum, we report the identification and confirmation of the FDA-approved drug ponatinib 
and 5 other known kinase inhibitors with potent in vitro MEKK2 inhibitory activity using 
two different MEKK2 enzymatic assay formats. Other than staurosporine-related molecules, 
this group of inhibitors represents some of the most potent MEKK2 enzyme assay inhibitors 
reported to date. These compounds may be useful tools in MEKK2 enzyme assays and 
possibly MEKK2-dependent cell-based assays. The ability of these compounds to inhibit 
MEKK2 function in cells will be assessed in future studies. Furthermore, these scaffolds 
may provide starting points for future structure-activity relationship (SAR) studies towards 
the design of highly MEKK2-selective inhibitor probes.
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• We screened a collection of known kinase inhibitors for inhibitors of MEKK2.
• Six compounds confirmed in MEKK2 ATPase and transphosphorylation 
enzyme assays.
• Good correlation observed between the two orthogonal MEKK2 activity assay 
formats.
• Ponatinib and clinical candidate AT9283 inhibited MEKK2 with IC50 of 5–18 
nM.
• Compounds are among the most potent in vitro MEKK2 inhibitors reported to 
date.
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Inhibitory activity of 6 known kinase inhibitors in the MEKK2 intrinsic ATPase assay. The 
compounds were tested at the indicated concentrations with the resultant raw signal 
normalized to maximum (DMSO only) and minimum (no MEKK2) controls, representing 
100% and 0% enzyme activity, respectively. Data points represent the average of two 
determinations per concentration and error bars represent standard deviation (SD). This plot 
is representative of three independent experiments.
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Inhibitory activity of 6 known kinase inhibitors in the MEKK2 transphosphorylation slot 
blot assay. (A) MEKK2 enzyme reactions using MKK6 as a substrate were stopped, 
transferred to a membrane via a slot blot apparatus and probed with phosphoMKK6-specific 
antibody detected by chemiluminescence. A representative slot blot image is shown with 
bands labeled as max (DMSO) and min (no MEKK2) controls and compound serial dilution. 
(B) The resultant digital image band intensities were converted to numerical data for IC50 
determination. The compounds were tested at the indicated concentrations with the resultant 
raw signal normalized to maximum (DMSO only) and minimum (no MEKK2) controls, 
representing 100% and 0% enzyme activity, respectively. Data points represent the average 
of two determinations per concentration and error bars represent standard deviation (SD). 
This plot is representative of two independent experiments.
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